Healthspan

Zone 2 training has become gospel in longevity circles—positioned as optimal for mitochondrial health. But the evidence doesn't support that claim. In our latest Beyond Healthspan episode, PhDc researcher Kristi Storoschuk explains why Zone 2's reputation might be overstated. The recommendation largely stems from observational data on elite endurance athletes who train 15–25+ hours weekly and have exceptional mitochondrial capacity. But extrapolating elite methods to the general population ignores a critical variable: volume. When training time is limited, intensity becomes the determining factor for mitochondrial adaptation. Storoschuk's narrative review in Sports Medicine examined the evidence and concluded: current data does not support Zone 2 as optimal for improving mitochondrial or fatty acid oxidative capacity. Higher intensities appear more effective—especially in realistic training volumes. If the intensity being recommended doesn't maximize mitochondrial adaptation in 3–6 hours of weekly training, the advice may be counterproductive. Watch the full conversation: https://lnkd.in/gfx2fV-h

Caloric restriction extends lifespan across species by activating nutrient sensors that prioritize cellular maintenance over growth. But human adherence is poor—the discipline required, combined with sarcopenia risk and nutritional challenges, makes sustained CR impractical. SGLT-2 inhibitors sidestep this by creating a chronic energy deficit through forced glucosuria, engaging the same pathways without dietary restriction. This week's Research Review examines whether the magnitude of effect is sufficient. https://lnkd.in/gym62pnt

Calling Alzheimer's "Type 3 Diabetes" isn't just a metaphor. The brain becomes insulin resistant. Neurons starve despite abundant glucose. Tau tangles form when protective insulin signaling fails. Metabolic dysfunction may be upstream of the plaques and tangles we've spent decades targeting. Insulin doesn't just regulate blood sugar—it protects brain structure. It activates the PI3K/Akt pathway, which keeps GSK-3β suppressed. When insulin signaling breaks down, GSK-3β becomes overactive and hyperphosphorylates tau, causing it to detach from microtubules and aggregate into neurofibrillary tangles. At the same time, insulin-degrading enzyme (IDE) normally clears both insulin and amyloid-beta. But when flooded with insulin from peripheral hyperinsulinemia, IDE can't keep up with Aβ clearance. Amyloid accumulates. PET scans show this metabolic crisis 10-20 years before symptoms appear. Glucose metabolism collapses in the hippocampus and prefrontal cortex while neurons remain structurally intact. The energy deficit is the earliest detectable signal. Ketones bypass this entirely. β-hydroxybutyrate enters cells without insulin, converts directly into acetyl-CoA, and restores mitochondrial ATP production—even when glucose metabolism has failed. Early trials show MCT supplementation improves episodic memory in MCI patients. Modified ketogenic diets raise CSF Aβ₄₂ and reduce neurofilament light chain, suggesting disease modification rather than symptom masking. If metabolic failure drives pathology, targeting metabolism—not just downstream protein aggregates—may be where therapeutic progress happens. https://lnkd.in/gS6sygNe

The thymus stops producing new T cells around age 60. When immune surveillance falters, senescent cells accumulate—fueling chronic inflammation and accelerating decline in strength, metabolic health, and tissue function. These "zombie cells" enter a state of suspended animation when damaged beyond safe division. Originally a protective mechanism against cancer, senescence becomes destructive when cells persist and release inflammatory cytokines known as SASP. SASP signals disrupt surrounding tissue and recruit neighboring cells into senescence. This creates a chain reaction that contributes to sarcopenia, cardiovascular dysfunction, and insulin resistance. Resistance training may offer a way to counteract this. In a study of women with an average age of 72, resistance training 3 days per week for 5 months reduced senescent cell abundance in adipose tissue by 60%. Acute resistance sessions showed a 50% reduction in p16+ cells in muscle. Skeletal muscle releases over 3,000 myokines when activated—signaling molecules that modulate inflammation, tissue repair, and cellular senescence in organs far beyond the muscle itself. Strength predicts functional independence better than muscle mass alone. Neural efficiency—how effectively the brain recruits motor units—declines faster with age than muscle size. Resistance training preserves both, while clearing the dysfunctional cells that accelerate frailty. This week's Research Review examines the mechanisms behind these effects, what the data shows about senescent cell clearance, and why skeletal muscle is increasingly recognized as a regulatory organ critical to healthspan. https://lnkd.in/gJ4NzVmf

A systematic review of nearly 6,000 participants has revealed something unexpected about mitochondrial adaptations to exercise. Sprint interval training—brief, maximal-effort bursts lasting 4–90 seconds—produced 2–3x more mitochondrial growth per hour of training than traditional endurance protocols. This challenges a foundational assumption in exercise science: that volume is the primary driver of aerobic adaptation. It's not how long you train—it's how efficiently you trigger the cellular stress response. Researchers analyzed hundreds of studies comparing three training modalities: low-to-moderate continuous endurance, high-intensity intervals, and sprint intervals. When measured in absolute terms, all three increased mitochondrial content by roughly 23–27%. The gains looked equivalent. But when normalized per hour of actual exercise time, sprint interval training emerged as the most efficient stimulus—particularly for untrained and moderately trained individuals. Why does this matter? Because mitochondrial content is a core determinant of aerobic capacity, metabolic health, and resilience to age-related decline. The ability to generate ATP efficiently influences everything from endurance performance to insulin sensitivity to cellular repair. The implication: brief, high-intensity efforts may activate the same—or stronger—adaptive pathways as longer, moderate-intensity sessions, but in a fraction of the time. This doesn't invalidate endurance training. The review also found that continuous moderate-intensity work produced 5–10% greater capillary density than sprint protocols—an adaptation critical for oxygen delivery and substrate exchange. But it does reframe the question. For individuals with limited time or those seeking to maximize mitochondrial biogenesis per unit of effort, sprint interval training appears to deliver disproportionate returns. The mechanism likely involves greater recruitment of fast-twitch muscle fibers, sharper metabolic perturbations, and more robust activation of AMPK and PGC-1α—the master regulators of mitochondrial biogenesis. Baseline fitness was the strongest predictor of adaptation magnitude. Untrained individuals experienced pronounced gains regardless of modality. Well-trained individuals required higher-intensity protocols to continue progressing. Age, sex, and disease status had minimal influence on the ability to adapt—suggesting the cellular machinery governing mitochondrial growth remains responsive across populations. This week's Research Review examines the evidence behind training efficiency, capillarization trade-offs, and what these findings mean for optimizing aerobic adaptation. https://lnkd.in/ghHDc_wN

Studies show oxytocin administration can reduce sleep latency by 10–20 minutes and increase REM episodes by 10–15%. Not because oxytocin is a sedative—but because it may be recalibrating the autonomic nervous system's shift from sympathetic activation to parasympathetic recovery. Sleep isn't passive shutdown. It's an active transition requiring the body to downregulate stress signaling, suppress cortisol output, and engage restorative processes that depend on parasympathetic dominance. Oxytocin appears to facilitate this transition. Its receptors are expressed throughout the hypothalamus, which coordinates both circadian rhythms and autonomic balance. Oxytocin signaling dampens HPA-axis activity, reduces amygdala reactivity to perceived threats, and promotes the shift from sympathetic "fight-or-flight" toward parasympathetic "rest-and-digest" states. This explains why oxytocin's sleep effects show up most clearly in people with elevated baseline stress or autonomic dysregulation. When the nervous system remains locked in sympathetic overdrive, falling asleep becomes harder—not because of conscious anxiety, but because the biological infrastructure for sleep entry is still primed for vigilance. Experimental studies support this mechanism. Intranasal oxytocin administered 30–60 minutes before bedtime has been shown to reduce sleep onset time by 10–20 minutes in controlled trials. REM sleep episodes—the phase associated with emotional processing and memory consolidation—increased by 10–15% in some studies. Sleep efficiency improved by 5–10%. These improvements weren't uniform across all participants. The strongest effects appeared in individuals with higher baseline cortisol, chronic stress exposure, or pre-existing sleep disturbances. This suggests oxytocin may function less as a universal sleep aid and more as a regulator that restores balance when autonomic signaling is dysregulated. The broader pattern: sleep quality depends on the nervous system's ability to downshift after daily stress accumulation. When that downshift is impaired—whether by chronic HPA-axis activation, elevated evening cortisol, or sustained sympathetic tone—sleep architecture degrades. Oxytocin doesn't replace sleep hygiene or circadian alignment. But it may address an upstream bottleneck: the failure to transition out of stress physiology when rest is needed. Our latest Research Review examines oxytocin's role in sleep architecture, autonomic regulation, stress recovery, and what this reveals about the biological infrastructure required for restorative sleep. https://lnkd.in/geQZRneD

The microbiome of centenarians looks less like modern dysbiosis — and more like ecological balance. In this week’s Research Review, Dr. Makenna Lenover Moyer explores what extreme longevity reveals about microbial diversity, immune regulation, and the maintenance of gut–brain signaling across the lifespan. Rather than quick fixes, the review focuses on the ecological foundations of resilience. https://lnkd.in/gtiqzjkW

AMPK activation reduces PD-L1 expression on senescent cells. That single mechanistic step connects metabolic signaling to immune surveillance—and may explain why a diabetes drug designed to dump glucose into urine ends up clearing senescent cells. PD-L1 is an immune checkpoint protein. When expressed on cell surfaces, it binds to PD-1 receptors on T cells and NK cells, effectively telling them: don't attack. Healthy cells use this to avoid autoimmune damage. Cancer cells exploit it to evade destruction. Senescent cells do the same thing. As cells become senescent, PD-L1 expression increases. This allows them to persist despite secreting inflammatory SASP factors that would otherwise mark them for immune clearance. The immune system can see them—but the checkpoint signal blocks elimination. SGLT2 inhibitors appear to reverse this. In the Nature Aging study, canagliflozin treatment reduced PD-L1 levels on senescent cells through AMPK activation. When researchers blocked AMPK activity, PD-L1 stayed elevated and senescent cell clearance stopped. The pathway: SGLT2 inhibition → AMPK activation → PD-L1 downregulation → restored immune clearance. This isn't a metabolic effect. It's immune checkpoint modulation driven by an energy-sensing kinase. When PD-L1 drops, CD8+ T cells and NK cells regain the ability to recognize and eliminate senescent cells. The researchers confirmed this by depleting T cells in treated mice—senolytic effects disappeared entirely. The clearance mechanism is immune-dependent, not cytotoxic. This matters because it positions AMPK as a regulatory node linking metabolism to immune function. AMPK is typically discussed in the context of autophagy, mitochondrial biogenesis, and metabolic stress responses. But this research shows it's also directly modulating immune checkpoints on damaged cells. Metabolic signaling isn't separate from immune aging. It's regulating the same checkpoints that determine whether senescent cells persist or get cleared. The broader implication: interventions targeting AMPK—whether through SGLT2 inhibitors, metformin, exercise, or caloric restriction—may be doing more than improving glucose metabolism. They may be recalibrating immune surveillance at the cellular level. Our latest Research Review dissects the AMPK-PD-L1 axis, how immune checkpoint modulation drives senescent cell clearance, and what this mechanistic connection reveals about the convergence of metabolic and immune pathways in aging. https://lnkd.in/gcbeR4ZT

Muscle strength predicts longevity better than muscle size. Yet most research chases hypertrophy, not force production. Strength requires two systems: muscle fibers that contract, and motor neurons that recruit them. Both fail with age—driving frailty, falls, and loss of independence. Rapamycin presents a paradox. It suppresses mTOR, the master regulator of muscle growth. That should harm muscle. But low, intermittent dosing preserves both muscle quality and strength in aging. The mechanism: autophagy—cellular cleanup that clears damaged proteins and organelles. With age, mTOR stays chronically elevated. Autophagy shuts down. Waste builds up. Muscle quality degrades while size stays intact. Rapamycin breaks that cycle—dialing down excessive growth signaling while restoring the cellular maintenance that preserves contractile function. The question isn't whether rapamycin replaces resistance training. It's whether pharmacology and exercise can work together to preserve strength across the lifespan. This week's Research Review covers the animal data, neurological mechanisms, and clinical frameworks. https://lnkd.in/gecWS9cV

1. Low muscle mass predicts cognitive decline. Not because muscle and brain happen to deteriorate together—but because skeletal muscle sends biochemical signals directly to the brain. When muscle mass drops, so does the signaling that maintains memory and executive function. 🧵👇 2. The Canadian Longitudinal Study on Aging followed 8,279 adults over 3 years. 19.4% had low appendicular lean mass at baseline. Those participants showed significantly faster declines in executive function and smaller improvements in memory—even after controlling for activity, education, and baseline cognition. 3. Executive function dropped faster in the low muscle group. Animal naming declined by 0.6 versus 0.5 in those with normal muscle mass. Mental alternation and cognitive inhibition tests followed the same pattern—steeper losses when muscle was already compromised. 4. Memory didn't decline—it improved across the cohort, likely due to practice effects from repeated testing. But the gains were smaller in participants with low muscle mass: 0.3 words recalled versus 0.4 in those with normal ALM. 5. This wasn't explained by grip strength, BMI, or lifestyle factors. Low ALM remained an independent predictor of cognitive trajectory. The implication: muscle mass itself may be protective—not just as a marker of health, but as an active biological system. 6. Sarcopenia and cognitive decline share overlapping mechanisms. Both involve mitochondrial dysfunction, chronic low-grade inflammation, and impaired autophagy. Both accelerate after age 60, when the thymus stops producing new T cells and immune surveillance weakens. 7. But muscle also functions as an endocrine organ. During contraction, it releases myokines—signaling molecules that influence metabolism, inflammation, and neuroplasticity in distant tissues. Losing muscle may disrupt the biochemical crosstalk that keeps the brain resilient. 8. What the Canadian study suggests is a critical window. Cognitive trajectories begin diverging in the 60s and 70s based on muscle mass—years before clinical dementia. This may be when interventions matter most, while both systems are still responsive. https://lnkd.in/gwJaM_34